Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Report
December 30, 2010
Formulary Advantages in Oral Oncology Drugs: Health plans respond to generic entry, base formulary decisions on survival data
Private and Medicare plans will continue their receptiveness to oral oncology therapies over the next five years, but anticipated increases in coinsurance rates and copays will shift more of the cost…
